A Study of EXG102-031 in Participants With wAMD

Inclusion Criteria: 1. Male or female, age ≥ 50 years of age; 2. Diagnosis of wAMD and current active lesion in the study eye at Screening; 3. An ETDRS BCVA letter scores between 73 and 9 letters in the study eye; 4. Response to anti-VEGF treatment within 6 months prior to screening or at the time of screening introduction; 5. The study eye must be a Intraocular lens eye(post-cataract surgery status) and be at least 1 month post IOL implantation at enrollment; 6. Voluntarily agree to participate in the clinical trial, understand the trial procedures, and be capable of signing the informed consent form before screening. Exclusion Criteria: 1. Presence of any ocular disease or history of disease in the study eye other than wAMD that may affect central visual acuity and/or macular detection; 2. Presence in the study eye of CNV or macular pathology pathography due to causes other than wAMD; 3. The study eye has severe and irreversible retinal structural damage involving the fovea (such as retinal pigment epithelial (RPE) atrophy, retinal fibrosis, laser scars, dense hard exudation); Or other retinal damage in the target eye that, in the opinion of the investigator, may impede visual improvement after resolution of macular edema ; 4. Subretinal hemorrhage accumulating the central fovea of the study eye, with an area of hemorrhage ≥ 4 optic disc diameters; 5. Presence of advanced glaucoma or uncontrolled ocular hypertension in the study eye; 6. Prior receipt of any ocular or systemic gene therapy agent.